Safety and Usefulness of Intracoronary Acetylcholine 200 μg Into the Left Coronary Artery as Vasoreactivity Testing: Comparisons With Intracoronary Acetylcholine Maximum 100 μg

Shozo Sueda,Yutaka Hayashi,Hiroki Ono,Tomoki Sakaue,Shuntaro Ikeda
DOI: https://doi.org/10.1002/clc.70001
2024-10-03
Clinical Cardiology
Abstract:Comparisons of the vasoreactivity testing results after propensity score matching. After propensity score matching, there are no differences regarding positive spasms, usual chest pain, or major complications between patients with a maximum ACh of 200 μg and those with a maximum ACh of 100 μg before August 2012. However, the frequency of unusual chest pain in patients with a maximum ACh of 200 μg is markedly higher than in those with a maximum ACh of 100 μg before August 2012 after propensity score matching. Objectives We retrospectively analyzed the usefulness and safety of intracoronary acetylcholine (ACh) 200 μg into the left coronary artery (LCA) as vasoreactivity testing compared with intracoronary ACh 100 μg. Methods We recruited 1433 patients who had angina‐like chest pain and intracoronary ACh testing in the LCA, including 1234 patients with a maximum ACh 100 μg and 199 patients with a maximum ACh 200 μg. ACh was injected in incremental doses of 20/50/100/200 μg into the LCA. Positive spasm was defined as ≥ 90% stenosis, usual chest pain, and ischemic electrocardiogram (ECG) changes. Results The incidence of coronary constriction ≥ 90%, usual chest pain, and ischemic ECG changes with a maximum ACh of 100 μg was markedly higher than that with a maximum ACh of 200 μg. The frequency of unusual chest pain in patients with a maximum ACh of 200 μg was higher than that in those with a maximum ACh of 100 μg (13% vs. 3%, p
cardiac & cardiovascular systems
What problem does this paper attempt to address?